121 related articles for article (PubMed ID: 11137650)
1. In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
Dhople AM
Int J Antimicrob Agents; 2001 Jan; 17(1):57-61. PubMed ID: 11137650
[TBL] [Abstract][Full Text] [Related]
2. In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648.
Dhople AM
Arzneimittelforschung; 2001; 51(6):501-5. PubMed ID: 11455683
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
Dhople AM; Namba K
J Antimicrob Chemother; 2002 Nov; 50(5):727-9. PubMed ID: 12407131
[TBL] [Abstract][Full Text] [Related]
4. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
5. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
[TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
[TBL] [Abstract][Full Text] [Related]
7. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA; Gardner GD
Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
[TBL] [Abstract][Full Text] [Related]
8. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
9. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
[TBL] [Abstract][Full Text] [Related]
10. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
11. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
Inderlied CB; Barbara-Burnham L; Wu M; Young LS; Bermudez LE
Antimicrob Agents Chemother; 1994 Aug; 38(8):1838-43. PubMed ID: 7986017
[TBL] [Abstract][Full Text] [Related]
12. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
[TBL] [Abstract][Full Text] [Related]
14. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
Dhople AM; Namba K
J Chemother; 2003 Feb; 15(1):47-52. PubMed ID: 12678414
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
Dhople AM; Ibanez MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
18. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
20. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
Mor N; Simon B; Heifets L
Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
